A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

• Status: Active, not recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Treatments: Angiopeptin; Lanreotide; Octreotide; Somatostatin

Criteria

Inclusion Criteria:

• Willing and able to provide written informed consent for the trial

• ≥ 18 years of age

• Histologically- or cytologically- confirmed locally advanced or metastatic WDNET

• SSA therapy is recommended by physician for disease management, and has not yet begun

• ECOG performance status of 0, 1, or 2

Exclusion Criteria:

• Currently participating in a study of an investigational agent

• Prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day 1 or not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent

*Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study

• No concurrent chemotherapy or targeted small molecule therapy

• If received major surgery, not recovered adequately from the toxicity and/or complications from the intervention prior to starting the study

• Known additional malignancy that is progressing or requires active treatment

• Active infection requiring systemic therapy

• Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial